Aug 2026· Cancers· Vol 18· 0 citations· 321 references
Medicine
TL;DR
This review summarizes emerging therapeutic strategies for EOC, their mechanisms of action, and their potential to overcome treatment resistance, and covers molecularly targeted therapies, immunotherapies, metabolic and epigenetic approaches, cellular and gene therapies, targeted drug-delivery systems, and locoregional and physical modalities.
Abstract
Simple Summary Ovarian cancer remains a major therapeutic challenge because many patients eventually experience disease recurrence and develop resistance to available treatments. Although recent therapeutic advances have improved outcomes in selected patient populations, there remains an urgent need for effective strategies to prevent or overcome treatment resistance. In this review, we summarize recent developments in ovarian cancer therapy, with particular emphasis on approaches targeting tumor-intrinsic biology, antitumor immunity, cancer metabolism, epigenetic regulation, and emerging cellular, genetic, and physical treatment modalities. We examine how these strategies may restore therapeutic sensitivity, delay disease progression, and improve clinical outcomes. Finally, we highlight personalized treatment selection, biomarker development, and rational combination therapies as key priorities for future research and clinical translation in ovarian cancer.
Simple Summary Gastrointestinal cancers remain among the most challenging diseases to treat because many tumors contain complex immune system suppression mechanisms that stop the body from destroying cancer cells. While current immunotherapy drugs have transformed care for a small group of patients, most gastrointestinal tumors quickly resist these treatments. This review explains how cancer cells bypass standard therapies and highlights next-generation immune targets currently being developed to overcome this resistance. We examine how combining new immune-boosting drugs with traditional treatments like chemotherapy, radiation, and novel targeted therapies can weaken cancer defenses. Finally, we explore advanced blood tests and digital tissue profiling methods designed to help doctors predict which patients will benefit most from these therapies. By connecting basic tumor biology with innovative clinical strategies, this review aims to help researchers design smarter, more focused and effective treatment combinations for patients with gastrointestinal cancers.
This review summarizes the current knowledge on breast cancer, including its epidemiology, anatomy and biology, etiological factors, molecular pathogenesis, diagnostic approaches, and clinically relevant biomarkers, while highlighting recent advances in antibody-drug conjugates, PARP inhibitors, nanotechnology-based drug delivery systems, artificial intelligence, and precision medicine.
Subham Kumar Singh, Aditya Rai· GLOBAL JOURNAL OF PHARMACEUT...· 0 citations
A comprehensive overview of emerging and targeted therapeutic strategies in colorectal cancer, with emphasis on their molecular basis and clinical relevance, highlights a shift toward precision oncology for improved management of colorectal cancer.
Debgopal Ganguly, Ananta Choudhury, Himangshu Deka et al.· Clinical and Translational O...· 0 citations
This review presents a systematic synthesis of the principal tumor immunotherapy strategies and their corresponding resistance mechanisms. Immunotherapies—including antibody-based therapies, adoptive cell therapies, immune modulators, and novel approaches such as oncolytic viruses and cancer vaccines—work by stimulating or enhancing the patient's immune system to target cancer cells. Nevertheless, they commonly encounter resistance in clinical applications. Resistance mechanisms predominantly stem from tumor-intrinsic factors and tumor microenvironment (TME) factors. To surmount resistance, combination therapies and personalized treatment strategies grounded in TME profiling and biomarkers represent critical future directions.
The evolving biological basis of therapeutic resistance is examined and how emerging treatment strategies may be integrated into biologically informed clinical development is discussed to improve patient selection, guide therapeutic sequencing, and increase the durability of treatment benefit in extensive-stage SCLC.
Jun Kim, Seounghun Kang· Pharmaceuticals· 0 citations
This review systematically outlines the mechanistic underpinnings of multiple major RCD subtypes in OC, with a focused summary of advances in innovative small-molecule compounds targeting these pathways, to provide novel insights and directions for precision therapy in OC.
Yu Liu, Z. Geng, Baofu Jia et al.· Frontiers in Cell and Develo...· 0 citations
